AA Pharma Bromocriptine Use In Pregnancy & Lactation

Pregnancy: In patients receiving AA PHARMA BROMOCRIPTINE, immunological confirmation of suspected conception should be performed as soon as possible and treatment stopped unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus. In any event, the patient must be monitored closely throughout pregnancy for signs and symptoms which may develop if a previously undetected prolactin-secreting tumour enlarges.
In human studies with bromocriptine, there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took bromocriptine during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.
Patients with pronounced enlargement of the sella turcica or a visual defect should, in the first instance, be treated by surgery and/or radiotherapy. If pregnancy occurs in the presence of a pituitary microadenoma, close supervision throughout pregnancy is essential. This includes regular checking of the visual fields.
Small prolactin-secreting adenomas not detected previously may rapidly increase in size during pregnancy. Optic nerve compression may occur and emergency pituitary surgery or other appropriate measures may be necessary.